Head-rush sensation composition, liquid formulation, nicotine liquid formulation, and preparation method therefor and use thereof

Abstract

The present invention relates to the technical field of electronic atomization, and in particular, to a head-rush sensation composition, a liquid formulation, a nicotine liquid formulation, and a preparation method therefor and the use thereof. The head-rush sensation composition comprises theanine, γ-aminobutyric acid, and magnolol. Specific substances are selected as raw material components of the head-rush sensation composition. Under the synergistic effect of the raw material components, the sense of satisfaction of a zero-nicotine liquid formulation or a low-nicotine liquid formulation is enhanced, thereby achieving the physiological objective of addiction relief.

Description

A composition that induces a feeling of nausea, a liquid formulation, a nicotine liquid formulation, a method for preparing the same and its application.

[0001] Cross-reference of related applications

[0002] This application claims priority to Chinese Patent Application No. 202410674616.0, filed on May 28, 2024, entitled "A Headache-Relieving Composition, Liquid Formulation, Nicotine Liquid Formulation and its Preparation Method and Application", the entire contents of which are incorporated herein by reference. Technical Field

[0003] This application relates to the field of electronic atomization technology, specifically to an intoxicating composition, a liquid formulation, a nicotine liquid formulation, and their preparation methods and applications. Background Technology

[0004] E-cigarettes are smoking cessation products that do not deliver nicotine through tobacco vapor. Instead, they deliver nicotine into the bloodstream, effectively reducing tobacco intake and helping smokers quit, similar to nicotine replacement therapy. E-cigarettes mainly consist of three parts: a cartridge, an atomizer, and a power source. The cartridge is the container for the liquid nicotine formulation, whose main components are nicotine, propylene glycol, glycerol, and flavorings. The atomizer, powered by a battery, atomizes the liquid nicotine in the cartridge into an aerosol with a specific aroma for the user. Nicotine primarily provides a feeling of satisfaction. Nicotine (also known as tobacco) is an acetylcholine receptor agonist. Its affinity for acetylcholine receptors is higher than that of the neurotransmitter acetylcholine secreted by the body itself. Ingesting a small amount of nicotine is equivalent to increasing the amount of acetylcholine neurotransmitter in the body, leading to an increase in dopamine secretion from neurons, resulting in feelings of pleasure, euphoria, and relaxation. However, excessive nicotine intake can cause vomiting and nausea, and in severe cases, death. To prevent nicotine abuse and protect public health and safety, countries have strictly regulated nicotine products, limiting nicotine content to 20mg / g or less. However, this limitation reduces the satisfying vaping experience for consumers. Currently, manufacturers are trying to improve the satisfaction by altering the proportion and content of organic acids, but the effect is limited. Many countries also promote zero-nicotine e-vaporizers. Zero-nicotine products do not have the problem of nicotine addiction. Currently, the zero-nicotine liquid formulations used in these devices mainly feature rich flavors and a cooling sensation. However, because they do not contain nicotine, existing zero-nicotine liquid formulations lack the throat hit and intoxication sensation associated with nicotine, resulting in weak product satisfaction and failing to provide physiological relief for consumers. Summary of the Invention

[0005] The purpose of this application is to overcome the shortcomings of existing technologies that reduce or eliminate nicotine, resulting in weaker satisfaction, and to provide a euphoric composition, a liquid formulation, a nicotine liquid formulation, a method for preparing the same, and its application.

[0006] To achieve the above objectives, this application adopts the following technical solution:

[0007] This application provides a composition that provides a feeling of intoxication, the composition comprising theanine, γ-aminobutyric acid, and magnolol.

[0008] Optionally, the mass ratio of theanine, γ-aminobutyric acid and magnolol is (1-15):(1-20):(1-20).

[0009] This application provides a liquid formulation, wherein the raw material components of the liquid formulation include a head-soothing substance and an atomizing solvent;

[0010] The substance that causes a feeling of euphoria includes the aforementioned composition that causes a feeling of euphoria.

[0011] Optionally, the mass concentration of the euphoric substance in the liquid formulation is 5-30 mg / g.

[0012] Optionally, the atomizing solvent includes at least one of propylene glycol and glycerol;

[0013] And / or, the mass ratio of the atomizing solvent to the head-raising substance is (50-98.5):(0.5-3).

[0014] Optionally, the atomizing solvent is propylene glycol and glycerol;

[0015] The mass ratio of propylene glycol to glycerol is (1-90):(1-90).

[0016] Optionally, the raw material components of the liquid formulation may further include a throat-punching substance, which may include piperine.

[0017] Optionally, the mass ratio of the throat-throating substance to the head-raising substance is (0.01-1):(5-30).

[0018] Optionally, the raw material components of the liquid formulation may also include flavorings.

[0019] Optionally, the flavoring includes at least one of tobacco flavoring, fruit flavoring, and mint flavoring;

[0020] Optionally, the fruit flavoring includes at least one of mango flavoring, blueberry flavoring, and grape flavoring.

[0021] Optionally, the mass ratio of the head-soothing substance to the fragrance is (0.5-3):(20-50).

[0022] Optionally, the liquid formulation includes theanine, γ-aminobutyric acid, magnolol, piperine, flavoring, propylene glycol, and glycerol;

[0023] The mass ratio of theanine, γ-aminobutyric acid, magnolol, piperine, flavoring, propylene glycol and glycerol is (1-15):(1-20):(1-20):(0.01-1):(200-500):(0-1000):(0-1000);

[0024] Optionally, the mass ratio of theanine, γ-aminobutyric acid, magnolol, piperine, flavoring, propylene glycol and glycerol is (1-15):(1-20):(1-20):(0.01-1):(200-500):(1-1000):(1-1000).

[0025] This application provides a method for preparing the above-described liquid formulation, comprising the following steps:

[0026] The product is obtained by mixing the stimulating substance and the atomizing solvent, heating and stirring until homogeneous.

[0027] Optionally, the preparation method of the liquid formulation may further include the step of adding a throat-scratching substance.

[0028] Optionally, the method for preparing the liquid formulation may further include the step of adding flavoring.

[0029] This application provides a nicotine liquid formulation, wherein the raw material components of the nicotine liquid formulation include nicotine and the liquid formulation described above.

[0030] Optionally, the nicotine concentration in the nicotine liquid preparation is 10-20 mg / g.

[0031] Optionally, the raw material components of the nicotine liquid formulation may also include organic acids.

[0032] Optionally, the organic acid is calculated as a carboxyl group, and the molar ratio of the organic acid to the nicotine in the nicotine liquid preparation is (0.1-2):(0.1-1).

[0033] Optionally, the organic acid includes C3-C8 organic carboxylic acids;

[0034] Optionally, the organic acid includes at least one of C3-C8 monocarboxylic acids, C3-C8 dicarboxylic acids, and C3-C8 ternary carboxylic acids.

[0035] Optionally, the organic acid includes at least one of salicylic acid, citric acid, lactic acid, malic acid, benzoic acid, levulinic acid, tartaric acid, and succinic acid.

[0036] Optionally, the organic acid is benzoic acid;

[0037] Alternatively, the organic acid may be benzoic acid, lactic acid, or levulinic acid;

[0038] The mass ratio of benzoic acid, lactic acid and levulinic acid is (3-7):(2-5):(1-3).

[0039] Optionally, the nicotine liquid formulation includes: nicotine, organic acids, theanine, γ-aminobutyric acid, magnolol, flavoring, propylene glycol, and glycerol;

[0040] The mass ratio of nicotine, organic acid, theanine, γ-aminobutyric acid, magnolol, flavoring, propylene glycol and glycerol is (9-18):(4.5-18):(1-10):(1-10):(1-10):(200-500):(0-1000):(0-1000);

[0041] Optionally, the mass ratio of nicotine, organic acid, theanine, γ-aminobutyric acid, magnolol, flavor, propylene glycol and glycerol is (9-18):(4.5-18):(1-10):(1-10):(1-10):(200-500):(1-1000):(1-1000).

[0042] This application provides a method for preparing the above-mentioned nicotine liquid formulation, comprising the following steps:

[0043] The product is obtained by mixing nicotine, a stimulating substance, and an atomizing solvent, then heating and stirring until homogeneous.

[0044] Optionally, the method for preparing the nicotine liquid formulation may further include the step of adding an organic acid.

[0045] Optionally, the method for preparing the nicotine liquid formulation may further include the step of adding flavoring.

[0046] Optionally, the preparation method of the nicotine liquid formulation may further include the step of adding a throat-scratching substance.

[0047] The nicotine liquid formulation described in this application is used to enhance satisfaction, and further, to enhance user satisfaction.

[0048] This application does not specify the stirring method; optionally, the stirring method can be selected from mechanical stirring, mechanical vibration, or ultrasonic vibration.

[0049] This application provides an electronic cigarette e-liquid comprising the above-described euphoric composition, the above-described liquid formulation, or the above-described nicotine liquid formulation.

[0050] This application provides the use of the above-described euphoric composition, the above-described liquid formulation, or the above-described nicotine liquid formulation in a nebulizer.

[0051] Optionally, the atomizing device is an electronic atomizing device.

[0052] The beneficial effects of this application are:

[0053] The intoxication composition provided in this application comprises theanine, γ-aminobutyric acid (GABA), and magnolol. This specific intoxication composition can induce a similar intoxication effect in the brain to nicotine. The synergistic effect of theanine, GABA, and magnolol significantly enhances the stimulation of the human brain, resulting in a noticeable sense of satisfaction. Therefore, this application selects specific substances as raw material components of the intoxication composition. Through their synergistic effect, it enhances the satisfaction of zero-nicotine or low-nicotine liquid formulations, thereby achieving the user's physiological craving relief. Attached Figure Description

[0054] To more clearly illustrate the technical solutions in the specific embodiments of this application or the prior art, the drawings used in the description of the specific embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of this application. For those skilled in the art, other drawings can be obtained from these drawings without creative effort.

[0055] Figure 1. Average normalized heart rate graphs of Examples 1, 6, 10, 11 and 12 of this application;

[0056] Figure 2 shows the normalized heart rate graphs of Examples 1, 6, 10, 11 and 12 of this application. Detailed Implementation

[0057] The following embodiments are provided to better understand this application and are not limited to the preferred embodiments described herein. They do not constitute a limitation on the content and scope of protection of this application. Any product that is the same as or similar to this application, derived by anyone under the guidance of this application or by combining features of this application with other prior art, falls within the scope of protection of this application.

[0058] For experiments not specifically described in the examples, the procedures or conditions should be followed according to the conventional experimental procedures described in the literature in this field. Reagents or instruments whose manufacturers are not specified are all commercially available conventional reagent products.

[0059] E-cigarettes are smoking cessation products that do not deliver nicotine through tobacco vapor. Instead, they deliver nicotine into the bloodstream, effectively reducing tobacco intake and helping smokers quit, similar to nicotine replacement therapy. E-cigarettes mainly consist of three parts: a cartridge, an atomizer, and a power source. The cartridge is the container for the liquid nicotine formulation, whose main components are nicotine, propylene glycol, glycerol, and flavorings. The atomizer, powered by a battery, atomizes the liquid nicotine in the cartridge into an aerosol with a specific aroma for the user. Nicotine primarily provides a feeling of satisfaction. Nicotine (also known as tobacco) is an acetylcholine receptor agonist. Its affinity for acetylcholine receptors is higher than that of the neurotransmitter acetylcholine secreted by the body itself. Ingesting a small amount of nicotine is equivalent to increasing the amount of acetylcholine neurotransmitter in the body, leading to an increase in dopamine secretion from neurons, resulting in feelings of pleasure, euphoria, and relaxation. However, excessive nicotine intake can cause vomiting and nausea, and in severe cases, death. To prevent nicotine abuse and protect public health and safety, countries have strictly regulated nicotine products, limiting nicotine content to 20mg / g or less. However, this limitation reduces the satisfying vaping experience for consumers. Currently, manufacturers are trying to improve the satisfaction by altering the proportion and content of organic acids, but the effect is limited. Many countries also promote zero-nicotine e-vaporizers. Zero-nicotine products do not have the problem of nicotine addiction. Currently, the zero-nicotine liquid formulations used in these devices mainly feature rich flavors and a cooling sensation. However, because they do not contain nicotine, existing zero-nicotine liquid formulations lack the throat hit and intoxication sensation associated with nicotine, resulting in weak product satisfaction and failing to provide physiological relief for consumers.

[0060] This application provides a composition that provides a feeling of euphoria, comprising theanine, γ-aminobutyric acid, and magnolol.

[0061] Theanine is a unique free amino acid found in tea, accounting for 1%-2% of the weight of dry tea. As a unique active ingredient in tea, theanine not only improves flavor and product quality, but it can also cross the cerebral vascular barrier and increase the secretion level of neurotransmitters in the brain, such as dopamine. This stimulates the dopamine reward pathway, thereby producing a feeling of satisfaction.

[0062] Gamma-aminobutyric acid (GABA) is widely found in plants such as tomatoes, potatoes, grapes, pumpkins, and tea. It is a common bioactive component in food and has been extensively studied in the functional dairy products, tea, and condiments industries, leading to a range of GABA-based products such as yogurt, candy, soy sauce, vinegar, and seafood seasonings. GABA is a natural active ingredient that, after ingestion, binds to and activates specific receptors, thereby exerting various physiological activities such as anti-anxiety, anti-aging, and blood pressure-lowering effects, and also having a calming effect on the nervous system.

[0063] Magnolol is the active ingredient in Magnolia officinalis plant extract, possessing sedative, hypnotic, anti-anxiety, and anti-epileptic effects. Magnolol can counteract exogenous morphine and inhibit the release of endogenous enkephalins, thus alleviating withdrawal symptoms. Simultaneously, it counteracts the excitatory effects of central neurotransmitters glutamate and N-methyl-D-aspartate (NMDA) receptors by promoting the release of β-endorphin and stimulating cannabinoid receptors.

[0064] This application's "hypnotic composition" can induce a similar euphoric effect in the brain to nicotine. The composition comprises theanine, gamma-aminobutyric acid (GABA), and magnolol. Through the synergistic effect of these specific components, it enhances the euphoric experience in the human body. When applied to zero-nicotine and low-nicotine products, it can increase the perceived euphoria and overall improve user satisfaction. Furthermore, the inventors have discovered that the synergistic effect of theanine, GABA, and magnolol in enhancing satisfaction is significantly better than that of any single substance or combination of two of these substances.

[0065] Therefore, this application selects specific substances as raw material components of the euphoric composition. Through their synergistic effect, the euphoric experience of zero-nicotine liquid formulations or low-nicotine liquid formulations is enhanced, and the user's satisfaction is increased, thereby achieving the purpose of physiological detoxification, while reducing its toxicity and addictiveness, and reducing health damage.

[0066] In some optional embodiments, the mass ratio of theanine, γ-aminobutyric acid and magnolol is (1-15):(1-20):(1-20). For example, the mass ratio of theanine, γ-aminobutyric acid and magnolol can be selected as 1:1:1, 1:1:2, 1:1:5, 1:1:7, 1:1:10, 1:1:15, 1:1:20, 2:2:1, 2:2:5, 2:2:10, 2:2:15, 2:2:19, 1:5:1, 1:10:1, 1:15:1, 1:20:1, 5:1:1, 10:1:1, 15:1:1, 20:1:1, 5:5:1, 1:5:1.

[0067] This application provides a liquid formulation whose raw material components include a euphoric substance and an atomizing solvent; the euphoric substance includes the aforementioned euphoric composition. The inventors have discovered that formulating the euphoric composition and the atomizing solvent into a zero-nicotine liquid formulation can enhance the satisfaction of the zero-nicotine liquid formulation, allowing consumers to achieve physiological craving relief.

[0068] In some optional embodiments, the mass concentration of the euphoric substance in the liquid formulation is 5-30 mg / g. For example, the mass concentration of the euphoric substance in the liquid formulation may be selected as 5 mg / g, 6 mg / g, 7 mg / g, 8 mg / g, 9 mg / g, 10 mg / g, 11 mg / g, 12 mg / g, 13 mg / g, 14 mg / g, 15 mg / g, 16 mg / g, 17 mg / g, 18 mg / g, 19 mg / g, 20 mg / g, 21 mg / g, 22 mg / g, 23 mg / g, 24 mg / g, 25 mg / g, 26 mg / g, 27 mg / g, 28 mg / g, 29 mg / g, or 30 mg / g.

[0069] In some optional embodiments, the atomizing solvent may be a conventional atomizing solvent in the art, including but not limited to at least one of propylene glycol and glycerol; optionally, the mass ratio of the atomizing solvent to the stimulating substance is (50-98.5):(0.5-3), for example, the mass ratio of the atomizing solvent to the stimulating substance may be 98.5:0.5, 98:0.5, 80:0.5, 90:0.5, 85:0.5, 70:0.5, 75:0.5, 60:0.5, 65:0.5, 50:0.5, 98.5:1, 98:1, 80:1, 90:1, 85:1, 70:1, 75:1, 60:1, 65:1, 50:1, 98.5: 1.5, 98:1.5, 80:1.5, 90:1.5, 85:1.5, 70:1.5, 75:1.5, 60:1.5, 65:1.5, 50:1.5, 98.5:2, 98:2, 80:2, 90:2, 85:2, 70:2, 75:2, 60:2, 65:2, 50:2, 98.5:2.5, 98:2.5, 80:2.5, 90:2.5, 85:2.5, 70:2.5, 75:2.5, 60:2.5, 65:2.5, 50:2.5, 98.5:3, 98:3, 80:3, 90:3, 85:3, 70:3, 75:3, 60:3, 65:3, 50:3. Optionally, the atomizing solvent is propylene glycol and glycerol. The mass ratio of propylene glycol to glycerol is (1-90):(1-90), for example, the mass ratio of propylene glycol to glycerol can be 8:2, 7:3, 6:4, 5:5, 4:6, 3:7, 2:8, 1:10, 10:1, 1:9, or 9:1. The addition of the atomizing solvent in this application can better dissolve the raw material components, effectively improve the atomization efficiency of the intoxicating substance, and increase the satisfaction.

[0070] In some alternative embodiments, the raw material components of the liquid formulation also include a throat-punching substance, such as piperine. Piperine is an alkaloid, the source of the spiciness of pepper, and its most important bioactive component. Piperine is a regulator of human transient receptor potential (TRP) channels. Similar to nicotine, piperine activates TRP channels, producing a throat-punching sensation such as pain, irritation, or tingling, which, in conjunction with a tingling sensation, enhances the user's sense of satisfaction. Furthermore, piperine also inhibits enzymes that play important roles in drug metabolism. By inhibiting drug metabolism, piperine may improve the bioavailability of many compounds.

[0071] In some optional embodiments, the mass ratio of the throat hit substance to the head-throat sensation substance is (0.01-1):(5-30). For example, the mass ratio of the throat hit substance to the head-throat sensation substance can be selected as 0.01:5, 0.05:5, 0.1:5, 0.3:5, 0.5:5, 0.8:5, 1:5, 0.01:10, 0.05:10, 0.1:10, 0.3:10, 0.5:10, 0.8:10, 1:10, 0.01:15, 0.05:15, 0.1:15, 0.3:15, 0.5:15, 0.8 :15, 1:15, 0.01:20, 0.05:20, 0.1:20, 0.3:20, 0.5:20, 0.8:20, 1:20, 0.01:25, 0.05:25, 0.1:25, 0.3:25, 0.5:25, 0.8:25, 1:25, 0.01:30, 0.05:30, 0.1:30, 0.3:30, 0.5:30, 0.8:30, 1:30.

[0072] In some optional embodiments, the raw material components of the liquid formulation further include flavorings. The flavorings can be conventionally available flavoring materials in the art, commercially available, or prepared using conventional methods with conventional components. For example, they can be selected as single-component flavorings or a mixture of multiple extracts. These include, but are not limited to, tobacco flavorings, fruit flavorings, and peppermint flavorings. Further, the fruit flavoring includes at least one of mango flavoring, blueberry flavoring, and grape flavoring; optionally, the mass ratio of the taste-enhancing substance to the flavoring is (0.5-3):(20-50), for example, the mass ratio of the taste-enhancing substance to the flavoring can be 0.5:20, 0.6:20, 0.7:20, 0.9:20, 1:20, 1.2:20, 1.5:20, 1.85:20, 2:20, 2.2:20, 2.5:20, 2.8:20, 3... 20, 0.5:25, 0.6:25, 0.7:25, 0.9:25, 1:25, 1.2:25, 1.5:25, 1.85:25, 2:25, 2.2:25, 2.5:25, 2.8:25, 3:25, 0.5:30, 0.6:30, 0.7:30, 0.9:30, 1:30, 1.2:30, 1.5:30, 1.85:30, 2:30, 2.2:30, 2.5:30, 2.8:30, 3 30, 0.5:35, 0.6:35, 0.7:35, 0.9:35, 1:35, 1.2:35, 1.5:35, 1.85:35, 2:35, 2.2:35, 2.5:35, 2.8:35, 3:35, 0.5:40, 0.6:40, 0.7:40, 0.9:40, 1:40, 1.2:40, 1.5:40, 1.85:40, 2:40, 2.2:40, 2.5:40, 2.8:40 3:40, 0.5:45, 0.6:45, 0.7:45, 0.9:45, 1:45, 1.2:45, 1.5:45, 1.85:45, 2:45, 2.2:45, 2.5:45, 2.8:45, 3:45, 0.5:50, 0.6:50, 0.7:50, 0.9:50, 1:50, 1.2:50, 1.5:50, 1.85:50, 2:50, 2.2:50, 2.5:50, 2.8:50.

[0073] In some optional embodiments, the liquid formulation comprises theanine, γ-aminobutyric acid, magnolol, piperine, flavoring, propylene glycol, and glycerol; the mass ratio of theanine, γ-aminobutyric acid, magnolol, piperine, flavoring, propylene glycol, and glycerol is (1-15):(1-20):(1-20):(0.01-1):(200-500):(0-1000):(0-1000); further optionally, the mass ratio of theanine, γ-aminobutyric acid, magnolol, piperine, flavoring, propylene glycol, and glycerol is (…). 1-15):(1-20):(1-20):(0.01-1):(200-500):(1-1000):(1-1000), for example, the mass ratio of theanine, γ-aminobutyric acid, magnolol, piperine, flavoring, propylene glycol and glycerol can be selected as 3:3:1:0.1:200:200:400, 5:5:2:1:300:200:400, 2:2:1:0.1:200:200:400, 10:10:20:0.1:500:100:600.

[0074] This application provides a method for preparing the above-mentioned liquid formulation, comprising the following steps: mixing the numbing agent and the atomizing solvent, and then heating and stirring until homogeneous to obtain the product.

[0075] In some alternative embodiments, the preparation method of the liquid formulation further includes the step of adding a throat-scratching substance.

[0076] In some alternative embodiments, the preparation method of the liquid formulation further includes the step of adding flavoring.

[0077] This application does not specify the heating and stirring temperature or time, as long as the raw materials can be dissolved. Optionally, the dissolution temperature should not exceed 100℃. Optionally, the heating and stirring temperature can be 40-65℃, and the heating and stirring time can be 20-30 minutes. This application does not specify the mixing method or the mixing order. Optionally, in this application, all raw materials can be mixed and then heated to dissolve, or some raw materials can be mixed and dissolved first, and then the remaining raw materials can be mixed and dissolved.

[0078] In some optional embodiments, the preparation method of the liquid formulation includes the following steps: mixing the euphoric substance and the atomizing solvent, heating at 40-65°C for 20-30 minutes to dissolve and mix evenly, cooling to 10-35°C, adding the fragrance and stirring for 5-40 minutes to mix evenly, to obtain the liquid formulation.

[0079] This application also provides a nicotine liquid formulation, the raw material components of which include nicotine and the aforementioned liquid formulation. The low-nicotine content nicotine liquid formulation of this application includes the aforementioned intoxicating substances, which can enhance the intoxication effect of the nicotine liquid formulation, thereby increasing the satisfaction brought to the user by the nicotine liquid formulation, and solving the problem of reduced user satisfaction due to the reduced nicotine content in low-nicotine products.

[0080] In some optional embodiments, the nicotine concentration in the nicotine liquid formulation is 10-20 mg / g. For example, the nicotine concentration in the nicotine liquid formulation may be 10 mg / g, 11 mg / g, 12 mg / g, 13 mg / g, 14 mg / g, 15 mg / g, 16 mg / g, 17 mg / g, 18 mg / g, 19 mg / g, or 20 mg / g.

[0081] In some optional embodiments, the raw material components of the nicotine liquid formulation further include organic acids. Optionally, the organic acid includes C3-C8 organic carboxylic acids; more preferably, the organic acid includes at least one of C3-C8 monocarboxylic acids, C3-C8 dicarboxylic acids, and C3-C8 ternary organic carboxylic acids. Even more preferably, the organic acid includes at least one of salicylic acid, citric acid, lactic acid, malic acid, benzoic acid, levulinic acid, tartaric acid, and succinic acid.

[0082] In some optional embodiments, the molar ratio of organic acid to nicotine in the nicotine liquid formulation, calculated based on carboxyl groups, is (0.1-2):(0.1-1); for example, optionally, the molar ratio of organic acid to nicotine in the nicotine liquid formulation, calculated based on carboxyl groups, is 0.1:0.1, 0.3:0.1, 0.5:0.1, 0.56:0.1, 0.7:0.1, 0.8:0.1, 0.9:0.1, 1:0.1, 1.2:0.1, 1.5:0.1, 1.56:0.1, 1.8:0.1, 2:0.1, 0.1:0.5, 0.3:0.5, 0.5:0.5, 0.56:0.5, 0.7: 0.5, 0.8:0.5, 0.9:0.5, 1:0.5, 1.2:0.5, 1.5:0.5, 1.56:0.5, 1.8:0.5, 2:0.5, 0.1:0.7, 0.3:0.7, 0.5:0.7, 0.56:0.7, 0.7:0.7, 0.8:0.7, 0.9:0.7, 1:0.7, 1.2:0.7, 1.5:0.7, 1.56:0.7, 1.8:0.7, 2:0.7, 0.1:1, 0.3:1, 0.5:1, 0.56:1, 0.7:1, 0.8:1, 0.9:1, 1:1, 1.2:1, 1.5:1, 1.56:1, 1.8:1, 2:1. After adding nicotine and a high-energy composition, the inventors further discovered that organic acids and their amounts affect the feeling of satisfaction. Changing the molar ratio of organic acids to nicotine alters the acid-base environment in the throat, modulating the throat hit during aerosol entry into the lungs, and further optimizing the feeling of satisfaction.

[0083] In some alternative embodiments, the organic acid may be benzoic acid.

[0084] In some optional embodiments, the organic acid may be benzoic acid, lactic acid, and levulinic acid; the mass ratio of the benzoic acid, lactic acid, and levulinic acid is (3-7):(2-5):(1-3). For example, the mass ratio of the organic acid may be 3:2:1, 4:2:1, 5:2:1, 6:2:1, 7:2:1, 3:3:1, 4:3:1, 5:3:1, 6:3:1, 7:3:1, 3:4:1, 4:4:1, 5:4:1, 6:4:1, 7:4:1, 3:5:1, 4:5:1, 5:5:1, 6:5:1, 7:5:1, 3:2:2, 4:2:2, 5:2:1. 2, 6:2:2, 7:2:2, 3:3:2, 4:3:2, 5:3:2, 6:3:2, 7:3:2, 3:4:2, 4:4:2, 5:4:2, 6:4:2, 7:4:2, 3:5:2, 4:5:2, 5:5:2, 6:5:2, 7:5:2, 3:2:3, 4:2:3, 5:2:3, 6:2:3, 7:2:3, 3:3:3, 4:3:3, 5:3:3, 6:3:3, 7:3:3, 3:4:3, 4:4:3, 5:4:3, 6:4:3, 7:4:3, 3:5:3, 4:5:3, 5:5:3, 6:5:3, 7:5:3, 3.2:2.2:1.4.

[0085] In some optional embodiments, the nicotine liquid formulation comprises: nicotine, organic acid, theanine, γ-aminobutyric acid, magnolol, flavoring, propylene glycol, and glycerol; wherein the mass ratio of nicotine, organic acid, theanine, γ-aminobutyric acid, magnolol, flavoring, propylene glycol, and glycerol is (9-18):(4.5-18):(1-10):(1-10):(1-10):(200-500):(0-1000):(0-1000); optionally, the nicotine, organic acid, theanine, γ-aminobutyric acid, magnolol, flavoring, propylene glycol, and glycerol are... The mass ratio of alcohol to glycerol is (9-18):(4.5-18):(1-10):(1-10):(1-10):(200-500):(1-1000):(1-1000). For example, optionally, the mass ratio of nicotine, organic acid, theanine, γ-aminobutyric acid, magnolol, fragrance, propylene glycol and glycerol is 9:5:3:3:1:200:100:500, 18:13.6:5:3:3:200:100:500, or 18:15:9:9:5:400:500:100.

[0086] This application provides a method for preparing the above-mentioned nicotine liquid formulation, comprising the following steps: mixing nicotine, a euphoric substance and an atomizing solvent, and then heating and stirring until homogeneous to obtain the final product.

[0087] In some alternative embodiments, the preparation method of nicotine liquid formulations may further include the step of adding flavoring.

[0088] In some alternative embodiments, the preparation method of nicotine liquid formulations further includes the step of adding organic acids.

[0089] In some alternative embodiments, the preparation method of nicotine liquid formulations further includes the step of adding a throat-scratching substance.

[0090] This application does not specify the heating and stirring temperature or time, as long as the raw materials can be dissolved. Optionally, the dissolution temperature should not exceed 100℃. Optionally, the heating and stirring temperature can be 40-65℃, and the heating and stirring time can be 20-30 minutes. This application does not specify the mixing method or the mixing order. Optionally, in this application, all raw materials can be mixed and then heated to dissolve, or some raw materials can be mixed and dissolved first, and then the remaining raw materials can be mixed and dissolved.

[0091] In some optional embodiments, the preparation method of the nicotine liquid formulation includes the following steps: mixing nicotine, a euphoric substance and an atomizing solvent, heating at 40-65°C for 20-30 minutes to dissolve and mix evenly, cooling to 10-35°C, adding flavoring and stirring for 5-40 minutes to mix evenly, to obtain the nicotine liquid formulation.

[0092] This application provides an electronic cigarette e-liquid comprising the above-mentioned euphoric composition, the above-mentioned liquid formulation, or the above-mentioned nicotine liquid formulation.

[0093] This application also provides the use of the above-described euphoric composition, liquid formulation, or nicotine liquid formulation in a nebulizer. Optionally, the nebulizer is an electronic nebulizer.

[0094] The present application will be further described in detail below with reference to specific embodiments, which should not be construed as limiting the scope of protection claimed in the present application.

[0095] Example 1

[0096] This embodiment provides a method for preparing a liquid formulation, including the following steps:

[0097] Mix 0.5g theanine, 0.5g γ-aminobutyric acid, 0.5g honokiol, 23.5g propylene glycol and 40g glycerol, heat and stir in a water bath at 60°C for 20 minutes to mix evenly, cool to room temperature, add 35g grape flavoring, and continue stirring for 20 minutes to mix evenly to obtain the liquid preparation.

[0098] Example 2

[0099] This embodiment provides a method for preparing a liquid formulation, including the following steps:

[0100] Mix 0.5g theanine, 0.5g γ-aminobutyric acid, 0.5g magnolol, 0.03g piperine, 23.47g propylene glycol and 40g glycerol, heat and stir in a water bath at 60°C for 20 minutes to mix evenly, cool to room temperature, add 35g grape flavoring, and continue stirring for 20 minutes to mix evenly to obtain the liquid preparation.

[0101] Example 3

[0102] This embodiment provides a method for preparing a liquid formulation, including the following steps:

[0103] Mix 1g theanine, 1g γ-aminobutyric acid, 1g honokiol, 22g propylene glycol and 40g glycerol, heat and stir in a water bath at 60°C for 20 minutes to mix evenly, cool to room temperature, add 35g grape flavoring, and continue stirring for 20 minutes to mix evenly to obtain the liquid preparation.

[0104] Example 4

[0105] This embodiment provides a method for preparing a liquid formulation, including the following steps:

[0106] Mix 0.5g theanine, 0.5g γ-aminobutyric acid, 0.5g magnolol, 0.06g piperine, 23.44g propylene glycol and 40g glycerol, heat and stir in a water bath at 60°C for 20 minutes to mix evenly, cool to room temperature, add 35g grape flavoring, and continue stirring for 20 minutes to mix evenly to obtain the liquid preparation.

[0107] Example 5

[0108] This embodiment provides a method for preparing a liquid formulation, including the following steps:

[0109] Mix 0.8g theanine, 0.6g γ-aminobutyric acid, 0.8g honokiol, 22.8g propylene glycol and 40g glycerol, heat and stir in a water bath at 60°C for 20 minutes to mix evenly, cool to room temperature, add 35g grape flavoring, and continue stirring for 20 minutes to mix evenly to obtain the liquid preparation.

[0110] Example 6

[0111] This embodiment provides a method for preparing a nicotine liquid formulation, including the following steps:

[0112] Mix 1.8g nicotine with 1.36g benzoic acid, 0.4g theanine, 0.2g honokiol, 0.4g γ-aminobutyric acid, 15.84g propylene glycol and 40g glycerol. Heat and stir in a water bath at 60°C for 20 minutes until homogeneous. After cooling to room temperature, add 40g mango flavoring and continue stirring for 20 minutes until homogeneous to obtain the nicotine liquid preparation.

[0113] Example 7

[0114] This embodiment provides a method for preparing a nicotine liquid formulation, including the following steps:

[0115] 1.8g of nicotine, 0.32g of benzoic acid, 0.14g of levulinic acid, 0.22g of lactic acid, 0.4g of theanine, 0.2g of honokiol, 0.4g of γ-aminobutyric acid, 16.52g of propylene glycol, and 40g of glycerol were mixed and heated in a water bath at 60°C for 20 minutes until homogeneous. After cooling to room temperature, 40g of mango flavoring was added, and the mixture was stirred for another 20 minutes until homogeneous to obtain the nicotine liquid preparation.

[0116] Example 8

[0117] This embodiment provides a method for preparing a nicotine liquid formulation, including the following steps:

[0118] Mix 1.8g nicotine with 1.36g benzoic acid, 0.8g theanine, 0.4g honokiol, 0.8g γ-aminobutyric acid, 14.84g propylene glycol and 40g glycerol. Heat and stir in a water bath at 60°C for 20 minutes until homogeneous. After cooling to room temperature, add 40g mango flavoring and continue stirring for 20 minutes until homogeneous to obtain the nicotine liquid preparation.

[0119] Example 9

[0120] This embodiment provides a method for preparing a nicotine liquid formulation, including the following steps:

[0121] 1.8g of nicotine, 1.36g of benzoic acid, 0.2g of theanine, 0.1g of honokiol, 0.2g of γ-aminobutyric acid, 16.34g of propylene glycol and 40g of glycerol were mixed and heated and stirred in a water bath at 60°C for 20 minutes until homogeneous. After cooling to room temperature, 40g of mango flavoring was added and the mixture was stirred for another 20 minutes until homogeneous, thus obtaining the nicotine liquid preparation.

[0122] Example 10

[0123] This embodiment provides a method for preparing a nicotine liquid formulation, including the following steps:

[0124] 1.8g of nicotine, 1.36g of benzoic acid, 0.4g of theanine, 0.2g of magnolol, 0.4g of γ-aminobutyric acid, 0.03g of piperine, 15.81g of propylene glycol, and 40g of glycerol were mixed and heated in a water bath at 60°C for 20 minutes until homogeneous. After cooling to room temperature, 40g of mango flavoring was added, and the mixture was stirred for another 20 minutes until homogeneous to obtain the nicotine liquid preparation.

[0125] Example 11

[0126] This embodiment provides a method for preparing a nicotine liquid formulation, including the following steps:

[0127] 1.8g of nicotine, 1.36g of benzoic acid, 0.4g of theanine, 0.2g of magnolol, 0.4g of γ-aminobutyric acid, 0.01g of piperine, 15.83g of propylene glycol, and 40g of glycerol were mixed and heated in a water bath at 60°C for 20 minutes until homogeneous. After cooling to room temperature, 40g of mango flavoring was added, and the mixture was stirred for another 20 minutes until homogeneous to obtain the nicotine liquid preparation.

[0128] Example 12

[0129] This embodiment provides a method for preparing a nicotine liquid formulation, including the following steps:

[0130] 1.8g of nicotine, 0.64g of benzoic acid, 0.28g of levulinic acid, 0.44g of lactic acid, 0.4g of theanine, 0.2g of honokiol, 0.4g of γ-aminobutyric acid, 15.84g of propylene glycol, and 40g of glycerol were mixed and heated in a water bath at 60°C for 20 minutes until homogeneous. After cooling to room temperature, 40g of mango flavoring was added, and the mixture was stirred for another 20 minutes until homogeneous to obtain the nicotine liquid preparation.

[0131] Example 13

[0132] This embodiment provides a method for preparing a nicotine liquid formulation, including the following steps:

[0133] Mix 1.8g nicotine with 1.36g benzoic acid, 0.7g theanine, 0.3g honokiol, 0.5g γ-aminobutyric acid, 15.34g propylene glycol and 40g glycerol. Heat and stir in a water bath at 60°C for 20 minutes until homogeneous. After cooling to room temperature, add 40g mango flavoring and continue stirring for 20 minutes until homogeneous to obtain the nicotine liquid preparation.

[0134] Comparative Example 1

[0135] This comparative example provides a method for preparing a liquid formulation, comprising the following steps:

[0136] Mix 25g of propylene glycol and 40g of glycerol, heat and stir in a water bath at 60°C for 20 minutes until homogeneous, cool to room temperature, add 35g of blueberry flavoring, and continue stirring for 20 minutes until homogeneous to obtain the liquid preparation.

[0137] Comparative Example 2

[0138] This comparative example provides a method for preparing a nicotine liquid formulation, comprising the following steps:

[0139] Mix 0.9g nicotine, 0.68g benzoic acid, 23.42g propylene glycol and 40g glycerol, heat and stir in a water bath at 60°C for 20 minutes to mix evenly, cool to room temperature, add 35g blueberry flavoring, and continue stirring to mix evenly to obtain the nicotine liquid preparation.

[0140] Comparative Example 3

[0141] This comparative example provides a method for preparing a nicotine liquid formulation, comprising the following steps:

[0142] Mix 1.36g nicotine, 1.02g benzoic acid, 22.62g propylene glycol and 40g glycerol, heat and stir in a water bath at 60°C for 20 minutes to mix evenly, cool to room temperature, add 35g blueberry flavoring, and continue stirring for 20 minutes to mix evenly to obtain the nicotine liquid preparation.

[0143] Comparative Example 4

[0144] This comparative example provides a method for preparing a nicotine liquid formulation, comprising the following steps:

[0145] Mix 1.8g nicotine, 1.36g benzoic acid, 16.84g propylene glycol and 40g glycerol, heat and stir in a water bath at 60°C for 20 minutes to mix evenly, cool to room temperature, add 40g mango flavoring, and continue stirring for 20 minutes to mix evenly to obtain the nicotine liquid preparation.

[0146] Comparative Example 5

[0147] This comparative example provides a method for preparing a nicotine liquid formulation, comprising the following steps:

[0148] Mix 2.3g nicotine, 1.73g benzoic acid, 15.97g propylene glycol and 40g glycerol, heat and stir in a water bath at 60°C for 20 minutes to mix evenly, cool to room temperature, add 40g mango flavoring, and continue stirring for 20 minutes to mix evenly to obtain the nicotine liquid preparation.

[0149] Comparative Example 6

[0150] This comparative example provides a method for preparing a nicotine liquid formulation, comprising the following steps:

[0151] Mix 2.7g nicotine, 2.03g benzoic acid, 15.27g propylene glycol and 40g glycerol, heat and stir in a water bath at 60°C for 20 minutes to mix evenly, cool to room temperature, add 40g mango flavoring, and continue stirring for 20 minutes to mix evenly to obtain the nicotine liquid preparation.

[0152] Comparative Example 7

[0153] This comparative example provides a method for preparing a liquid formulation, comprising the following steps:

[0154] Mix 1.5g theanine, 23.5g propylene glycol and 40g glycerol, heat and stir in a water bath at 60°C for 20 minutes to mix evenly, cool to room temperature, add 35g grape flavoring, and continue stirring for 20 minutes to mix evenly to obtain the liquid preparation.

[0155] Comparative Example 8

[0156] This comparative example provides a method for preparing a liquid formulation, comprising the following steps:

[0157] Mix 1.5g γ-aminobutyric acid, 23.5g propylene glycol and 40g glycerol, heat and stir in a water bath at 60°C for 20 minutes to mix evenly, cool to room temperature, add 35g grape flavoring, and continue stirring for 20 minutes to mix evenly to obtain the liquid preparation.

[0158] Comparative Example 9

[0159] This comparative example provides a method for preparing a liquid formulation, comprising the following steps:

[0160] Mix 1.5g magnolol, 23.5g propylene glycol and 40g glycerol, heat and stir in a water bath at 60°C for 20 minutes to mix evenly, cool to room temperature, add 35g grape flavoring, and continue stirring for 20 minutes to mix evenly to obtain the liquid preparation.

[0161] Comparative Example 10

[0162] This comparative example provides a method for preparing a liquid formulation, comprising the following steps:

[0163] Mix 1.0g theanine, 0.5g γ-aminobutyric acid, 23.5g propylene glycol and 40g glycerol, heat and stir in a water bath at 60°C for 20 minutes to mix evenly, cool to room temperature, add 35g grape flavoring, and continue stirring for 20 minutes to mix evenly to obtain the liquid preparation.

[0164] Comparative Example 11

[0165] This comparative example provides a method for preparing a liquid formulation, comprising the following steps:

[0166] Mix 1.0g γ-aminobutyric acid, 0.5g honokiol, 23.5g propylene glycol and 40g glycerol, heat and stir in a water bath at 60°C for 20 minutes to mix evenly, cool to room temperature, add 35g grape flavoring, and continue stirring for 20 minutes to mix evenly to obtain the liquid preparation.

[0167] Comparative Example 12

[0168] This comparative example provides a method for preparing a liquid formulation, comprising the following steps:

[0169] Mix 0.5g theanine, 1.0g honokiol, 23.5g propylene glycol and 40g glycerol, heat and stir in a water bath at 60°C for 20 minutes to mix evenly, cool to room temperature, add 35g grape flavoring, and continue stirring for 20 minutes to mix evenly to obtain the liquid preparation.

[0170] Test case

[0171] This application uses a subjective tasting method to score various tasting indicators of the liquid formulations of Examples 1-13 and Comparative Examples 1-12. The tasting team consists of 12 people, all of whom have more than 5 years of experience in traditional cigarettes or e-cigarettes, and all of whom have undergone nicotine withdrawal for 12 hours before tasting.

[0172] Each participant received a tasting evaluation form. A blind sampling method was used to sample the liquid formulations from different embodiments and comparative examples. The sampling method involved randomly coding the different embodiments and comparative examples with a 3-digit number. Participants were nicotine-free for 10 hours the night before sampling. The sampling test was conducted at 10:00 AM on the day of sampling, using a RELX5 e-cigarette device (paired with samples from different embodiments and comparative examples). Participants inhaled 8 puffs of vapor (each puff lasting 3 seconds, with a 27-second interval between puffs). The vapor was briefly held in the mouth before being swallowed. Participants were not allowed to share their sampling experience and each scored their e-liquid sample on their evaluation form according to the evaluation indicators in Table 1. After sampling one sample, participants were required to abstain for 2 hours before sampling the next sample. The sampling test results are shown in Table 2 (the scores in Table 2 are average scores).

[0173] Table 1 Evaluation Indicators

[0174] Table 2. Smoking Scoring Data

[0175] The liquid formulation of Example 1 of this application uses three specific euphoric substances in a synergistic effect, and its satisfaction effect is significantly better than that of Comparative Examples 7-9 using one euphoric substance alone in equal quantities. It is also significantly better than that of Comparative Examples 10-11 using two euphoric substances in equal quantities in synergy, demonstrating that the euphoric composition of theanine, γ-aminobutyric acid, and magnolol can synergistically enhance user satisfaction. The satisfaction effects of the liquid formulations of Examples 1-5 of this application are all better than those of the nicotine liquid formulation of Comparative Example 2 with a nicotine content of 9 mg / g, and can even reach the satisfaction effect of the nicotine liquid formulation of Comparative Example 3 with a nicotine content of 13.6 mg / g. The satisfaction effects of the liquid formulations of Examples 6-13 of this application are all better than those of the nicotine liquid formulation of Comparative Example 4 with a nicotine content of 18 mg / g, and can even reach the satisfaction effect of the nicotine liquid formulation of Comparative Example 6 with a nicotine content of 27 mg / g.

[0176] Test Example 2

[0177] Heart rate tests were conducted on the liquid formulations prepared in Examples 1, 6, 10, 11, and 12 (hereinafter referred to as samples) during inhalation. The test method was as follows: the participants underwent nicotine withdrawal the night before the test, and the heart rate test was conducted at 9:00 AM on the day of the test. Before inhalation, a heart rate monitoring device (Lepu Xin'anbao ER1) was worn, and real-time changes in heart rate were monitored throughout the entire inhalation process. After the heart rate monitoring device was worn and adjusted, a baseline heart rate test was conducted for 2 minutes. After the heart rate stabilized, heart rate monitoring during inhalation began. A RELX5 nicotine device (used with samples from different examples and comparative examples) was used, and a total of 5 puffs of vapor were inhaled (each puff lasted 3 seconds, with a 27-second interval between adjacent puffs). The total inhalation time was approximately 2.5 minutes, and the time of inhalation for each puff was recorded. After inhalation, heart rate changes were monitored for another 1 minute, and then the experiment was terminated. After completing one sample, a 2-hour abstinence period was observed before the heart rate test was performed on the next sample. The test results are shown in Figures 1 and 2. In Figure 1, the normalized heart rate is the ratio of the average monitored heart rate to the average baseline heart rate during the abstinence process. In Figure 2, the normalized heart rate is the ratio of the real-time monitored heart rate during the abstinence process to the average baseline heart rate over the aforementioned 2 minutes.

[0178] As shown in Figures 1 and 2, the liquid formulation of Example 1, which uses theanine, γ-aminobutyric acid (GABA), and magnolol in synergy, has a significantly higher average normalized heart rate and average normalized heart rate than that of Comparative Example 10-12 (which uses two of the three substances, theanine, GABA, and magnolol, in equal quantities). This indicates that the combination of theanine, GABA, and magnolol has a more significant synergistic effect that can improve the user's satisfaction experience.

[0179] Obviously, the above embodiments are merely illustrative examples for clear explanation and are not intended to limit the implementation. Those skilled in the art will recognize that other variations or modifications can be made based on the above description. It is neither necessary nor possible to exhaustively list all possible implementations here. However, obvious variations or modifications derived therefrom are still within the scope of protection of this invention.

Claims

1. A composition that provides a feeling of euphoria, characterized in that, The euphoric composition includes theanine, γ-aminobutyric acid, and magnolol.

2. The composition for a feeling of euphoria according to claim 1, characterized in that, The mass ratio of theanine, γ-aminobutyric acid and magnolol is (1-15):(1-20):(1-20).

3. A liquid formulation, characterized in that, The raw material components of the liquid formulation include a headache-inducing substance and an atomizing solvent; The sensation-inducing substance includes the sensation-inducing composition according to claim 1 or 2.

4. The liquid formulation according to claim 3, characterized in that, The mass concentration of the euphoric substance in the liquid formulation is 5-30 mg / g.

5. The liquid formulation according to claim 3 or 4, characterized in that, The atomizing solvent includes at least one of propylene glycol and glycerol; And / or, the mass ratio of the atomizing solvent to the head-raising substance is (50-98.5):(0.5-3).

6. The liquid formulation according to any one of claims 3-5, characterized in that, The atomizing solvent is propylene glycol and glycerol; The mass ratio of propylene glycol to glycerol is (1-90):(1-90).

7. The liquid formulation according to any one of claims 3-6, characterized in that, The raw material components of the liquid formulation also include a throat-punching substance, which includes piperine.

8. The liquid formulation according to claim 7, characterized in that, The mass ratio of the throat-throating substance to the head-raising substance is (0.01-1):(5-30).

9. The liquid formulation according to any one of claims 3-8, characterized in that, The raw material components of the liquid preparation also include flavorings.

10. The liquid formulation according to claim 9, characterized in that, The flavoring includes at least one of tobacco flavoring, fruit flavoring, and peppermint flavoring; Optionally, the fruit flavoring includes at least one of mango flavoring, blueberry flavoring, and grape flavoring.

11. The liquid formulation according to claim 9 or 10, characterized in that, The mass ratio of the flavoring substance to the fragrance is (0.5-3):(20-50).

12. The liquid formulation according to any one of claims 3-11, characterized in that, The liquid formulation includes theanine, γ-aminobutyric acid, magnolol, piperine, flavoring, propylene glycol, and glycerol; The mass ratio of theanine, γ-aminobutyric acid, magnolol, piperine, flavoring, propylene glycol and glycerol is (1-15):(1-20):(1-20):(0.01-1):(200-500):(0-1000):(0-1000); Preferably, the mass ratio of theanine, γ-aminobutyric acid, magnolol, piperine, flavoring, propylene glycol and glycerol is (1-15):(1-20):(1-20):(0.01-1):(200-500):(1-1000):(1-1000).

13. A method for preparing a liquid formulation according to any one of claims 3-12, characterized in that, Includes the following steps: The product is obtained by mixing the stimulating substance and the atomizing solvent, heating and stirring until homogeneous.

14. The method for preparing the liquid formulation according to claim 13, characterized in that, It also includes the step of adding a throat-throating substance.

15. The method for preparing the liquid formulation according to claim 13 or 14, characterized in that, It also includes the step of adding flavoring.

16. A nicotine liquid formulation, characterized in that, The raw material components of the nicotine liquid formulation include nicotine and the liquid formulation according to any one of claims 3-12.

17. The nicotine liquid formulation according to claim 16, characterized in that, The nicotine concentration in the nicotine liquid preparation is 10-20 mg / g.

18. The nicotine liquid formulation according to claim 16 or 17, characterized in that, The raw material components of the nicotine liquid formulation also include organic acids.

19. The nicotine liquid formulation according to claim 18, characterized in that, The organic acid is calculated as a carboxyl group, and the molar ratio of the organic acid to the nicotine in the nicotine liquid preparation is (0.1-2):(0.1-1).

20. The nicotine liquid formulation according to claim 18 or 19, characterized in that, The organic acids include C3-C8 organic carboxylic acids; Optionally, the organic acid includes at least one of C3-C8 monocarboxylic acids, C3-C8 dicarboxylic acids, and C3-C8 ternary carboxylic acids.

21. The nicotine liquid formulation according to any one of claims 18-20, characterized in that, The organic acid includes at least one of salicylic acid, citric acid, lactic acid, malic acid, benzoic acid, levulinic acid, tartaric acid, and succinic acid.

22. The nicotine liquid formulation according to any one of claims 18-21, characterized in that, The organic acid is benzoic acid; Alternatively, the organic acid may be benzoic acid, lactic acid, or levulinic acid; The mass ratio of benzoic acid, lactic acid and levulinic acid is (3-7):(2-5):(1-3).

23. The nicotine liquid formulation according to any one of claims 16-22, characterized in that, The nicotine liquid formulation includes: nicotine, organic acids, theanine, γ-aminobutyric acid, magnolol, flavoring, propylene glycol, and glycerol; The mass ratio of nicotine, organic acid, theanine, γ-aminobutyric acid, magnolol, flavoring, propylene glycol and glycerol is (9-18):(4.5-18):(1-10):(1-10):(1-10):(200-500):(0-1000):(0-1000); Preferably, the mass ratio of nicotine, organic acid, theanine, γ-aminobutyric acid, magnolol, flavor, propylene glycol and glycerol is (9-18):(4.5-18):(1-10):(1-10):(1-10):(200-500):(1-1000):(1-1000).

24. A method for preparing a nicotine liquid formulation according to any one of claims 16-23, characterized in that, Includes the following steps: The product is obtained by mixing nicotine, a stimulating substance, and an atomizing solvent, then heating and stirring until homogeneous.

25. The method for preparing nicotine liquid formulation according to claim 24, characterized in that, It also includes the step of adding organic acids.

26. The method for preparing the nicotine liquid formulation according to claim 24 or 25, characterized in that, It also includes the step of adding flavoring.

27. The method for preparing the nicotine liquid formulation according to any one of claims 24-26, characterized in that, It also includes the step of adding a throat-throating substance.

28. An electronic cigarette e-liquid, characterized in that, Its raw material components include the euphoric composition according to any one of claims 1-2, the liquid formulation according to any one of claims 3-12, or the nicotine liquid formulation according to any one of claims 16-23.

29. The use of the euphoric composition of claim 1 or 2, the liquid formulation of any one of claims 3-12, or the nicotine liquid formulation of any one of claims 16-23 in a nebulizer.

30. The application according to claim 29, characterized in that, The atomizing device is an electronic atomizing device.

Images